Ocular Therapeutix Inc
Change company Symbol lookup
Select an option...
OCUL Ocular Therapeutix Inc
APO Apollo Global Management Inc
DTEC ALPS Disruptive Technologies ETF
$RUIRETAILT Russell 1000 RGS Retail Total Return
BAC Bank of America Corp
MA Mastercard Inc
AAPL Apple Inc
AA Alcoa Corp
AMD Advanced Micro Devices Inc
PFE Pfizer Inc
Go

Health Care : Pharmaceuticals | Small Cap Growth
Company profile

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.

Closing Price
$19.91
Day's Change
-0.17 (-0.85%)
Bid
--
Ask
--
B/A Size
--
Day's High
20.56
Day's Low
19.07
Volume
(Heavy Day)
Volume:
941,619

10-day average volume:
774,244
941,619

Display:

Providers:

UpdateCancel
6 providers
Today's News, January 20, 2021
Ocular Therapeutix(TM) Presents Interim Topline Data from the Phase 1 Clinical Trial of OTX-TIC in Patients with Primary Open Angle Glaucoma or Ocular Hypertension at the 10th Annual Glaucoma 360 New Horizons Forum

Ocular Therapeutix(TM), Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced plans to present data on OTX-TIC...(BusinessWire)

January 07, 2021
Ocular Therapeutix(TM) Promotes Michael Goldstein, MD, MBA, to President, Ophthalmology and Appoints Rabia Gurses Ozden, MD as Senior Vice President, Clinical Development

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the promotion of Michael Goldstein...(BusinessWire)

December 28, 2020
Ocular Therapeutix(TM) Announces Exercise of Underwriters' Option to Purchase Additional Shares

Ocular Therapeutix(TM), Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the underwriters of its...(BusinessWire)

December 22, 2020
Ocular Therapeutix(TM) Announces Submission to the FDA of a Supplemental New Drug Application for DEXTENZA(R) (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the submission of the supplemental New...(BusinessWire)

December 15, 2020
Ocular Therapeutix(TM) Announces Pricing of Public Offering of Common Stock

Ocular Therapeutix(TM), Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the pricing of an underwritten...(BusinessWire)

December 14, 2020
Ocular Therapeutix(TM) Announces Proposed Public Offering of Common Stock

Ocular Therapeutix(TM), Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has commenced an...(BusinessWire)

November 23, 2020
Ocular Therapeutix(TM) to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the Piper...(BusinessWire)

November 11, 2020
Ocular Therapeutix(TM) To Present Data at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the...(BusinessWire)

November 09, 2020
Ocular Therapeutix(TM) to Participate at Two Upcoming Investor Conferences

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate at the...(BusinessWire)

November 05, 2020
Ocular Therapeutix, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 5, 2020 / Ocular Therapeutix, Inc. (OCUL) (NASDAQ:OCUL) will be discussing their earnings results in their call to be held on November 5, 2020 at 4:30 PM Eastern Time. (Accesswire)

Ocular Therapeutix(TM) Reports Third Quarter 2020 Financial Results and Business Update

--DEXTENZA(R) Net Product Revenue in Third Quarter of $5.4 Million, a 280% Increase from the Prior Quarter --Reported Topline Phase 1 Results and Recently Initiated Phase 2 Clinical Trial of OTX-CSI for the Chronic Treatment of Dry Eye Disease (BusinessWire)

November 04, 2020
Ocular Therapeutix Announces Receipt of a Permanent Category I CPT Code from the American Medical Association for the Insertion of Intracanalicular Inserts

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that its application for the creation...(BusinessWire)

October 30, 2020
Ocular Therapeutix(TM) and AffaMed Therapeutics Announce License Agreement and Collaboration for DEXTENZA(R) and OTX-TIC in Asia

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced a license agreement and a...(BusinessWire)

October 23, 2020
Ocular Therapeutix(TM) To Report Third Quarter 2020 Financial Results

Ocular Therapeutix(TM), Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report third quarter...(BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.